Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Iodine concentrations of portal vein noninvasively identifies portal hypertension in liver cirrhosis

27 Oct 2019

Use of the iodine concentrations of the portal vein (ICPV) appears to be an expedient noninvasive tool in evaluating the portal venous pressure and identifying clinically significant portal hypertension in patients with liver cirrhosis, suggests a recent study.

The authors evaluated the accuracy of parameters measured using dual energy spectral computed tomography (LightSpeed CT750 HD) in 45 patients with liver cirrhosis who underwent percutaneous transhepatic portal vein puncture as part of their treatment for liver disease. They also conducted preoperative measurement of direct portal venous pressure. All patients underwent dual energy spectral computed tomography within 3 days prior to their operations.

Stepwise multivariate linear regression analysis revealed the independent associations of the ICPV (p<0.001) and hepatic parenchyma during the portal venous phase (p<0.004) and the alanine aminotransferase level (p<0.024) with the direct portal venous pressure.

The receiver operation characteristic analysis demonstrated a significantly higher area under the receiver operating characteristic of ICPV (p=0.944) for identifying clinically significant portal hypertension (≥10 mm Hg) compared with that of iodine concentrations of hepatic parenchyma (p=0.825) and the alanine aminotransferase level (p=0.301).

The threshold ICPV of 58.27 yielded a sensitivity, specificity, positive predictive value and negative predictive value of 93.8 percent, 69.2 percent, 88.2 percent and 81.8 percent, respectively.

“Early diagnosis of portal hypertension is imperative for timely treatment to reduce the mortality rate,” the authors said. “However, there is still no adequate method to noninvasively and accurately assess the portal hypertension in routine clinical practice.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.